Advertisement
UCB Announces Commercial Availability Of Zilbrysq In U.S. To Treat Generalized Myasthenia Gravis
(RTTNews) - Biopharmaceutical company UCB announced Wednesday that ZILBRYSQ (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
ZILBRYSQ was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.
ZILBRYSQ is available by prescription as a ready-to-use pre-filled syringe that is a once-daily administration. Healthcare providers who prescribe ZILBRYSQ must enroll in the ZILBRYSQ REMS because of the risk of serious meningococcal infections.
Myasthenia gravis is a rare, chronic, autoimmune neuromuscular disease, which is characterized by muscle weakness that worsens after periods of activity and improves after periods of rest.
UCB Announces U.S. Availability Of BIMZELX To Treat Adults With Moderate-to-Severe Plaque Psoriasis
Eurozone Inflation Steady At 2% ECB Target
U.S. Job Growth Misses Estimates In July, Previous Months' Numbers Revised Sharply Lower
Bay Street Likely To Open On Weak Note
U.S. Employment Rises Much Less Than Expected In July
FTSE 100 Down 0.55% As Trump's Tariff Moves Hurt Sentiment
Eurozone Manufacturing Activity Moves Closer To Stagnation
